Ipamorelin 5mg

Ipamorelin 5mg — Selective GH Secretagogue

When Raun et al. characterized Ipamorelin in 1998, they called it “the first growth hormone secretagogue receptor agonist with a selectivity for GH release similar to that displayed by GHRH” (European Journal of Endocrinology; PubMed 9849822). That selectivity is what defines this compound. Earlier GH-releasing peptides like GHRP-6 and GHRP-2 stimulated growth hormone but also pushed cortisol and prolactin levels higher. Ipamorelin does not — at GH-releasing concentrations in preclinical models, cortisol and prolactin remain at baseline levels. Buy Ipamorelin 5mg

Ipamorelin 5mg Specifications

Pharmacology and Receptor Signaling

Ipamorelin 5mg binds to the growth hormone secretagogue receptor type 1a (GHS-R1a), a G protein-coupled receptor expressed primarily in anterior pituitary somatotrophs. The binding triggers a phospholipase C-mediated signaling cascade: IP3/DAG release, intracellular calcium mobilization, and protein kinase C (PKC) activation, culminating in growth hormone exocytosis. EC50 has been measured at 1.3 nmol/L in rat pituitary cell assays, with peak GH response occurring at approximately 40 minutes post-administration and a circulating half-life of approximately 2 hours (Gobburu et al., Pharmaceutical Research, 1999). Buy Ipamorelin 5mg

What distinguishes ipamorelin from earlier GHS-R agonists (hexarelin, GHRP-6, GHRP-2) is its signaling selectivity. While those compounds activate GHS-R1a and also engage other pathways that elevate cortisol and prolactin, ipamorelin produces minimal cross-reactivity at GH-releasing concentrations. This selectivity makes it a valuable tool for researchers studying isolated GHS-R1a-mediated somatotroph activation without confounding adrenocorticotropic or lactotropic effects (Sinha et al., Transl Androl Urol, 2020; PMC7108996).

Research Applications Beyond Growth Hormone

The published literature on ipamorelin extends well beyond somatotroph activation. Svensson et al. examined its effects in bone mineral density studies using dual-energy X-ray absorptiometry (DEXA) and peripheral quantitative computed tomography (pQCT) in murine models, documenting changes in cortical and trabecular bone parameters (Svensson et al., The Journal of Endocrinology, 2000). Greenwood-Van Meerveld et al. investigated ipamorelin in postoperative gastric dysmotility models, where GHS-R1a agonism was associated with effects on gastric emptying rate and smooth muscle contractility (J Exp Pharmacol, 2012; PubMed 27186124).

Additional research contexts include the study of GHS-R1a constitutive activity (the receptor signals at approximately 50% of maximal capacity even without ligand binding), inverse agonism, and biased signaling — areas where ipamorelin serves as a reference agonist for characterizing receptor pharmacology (Holst et al., Molecular Endocrinology, 2003; PubMed 12893882).

Key Research Applications

• Selective GHS-R1a agonism and somatotroph signaling cascade characterization
• Comparative secretagogue studies — selectivity profiling against GHRP-6, GHRP-2, hexarelin
• Dual-pathway growth hormone axis research when paired with GHRH receptor agonists
• GHS-R1a constitutive activity and biased agonism investigations
• Bone metabolism and mineral density research models
• Gastrointestinal motility and smooth muscle contractility studies

Ipamorelin + CJC-1295: Dual-Receptor Axis Research

Ipamorelin (GHS-R1a agonist) and CJC-1295 (GHRH receptor agonist) target different receptors within the same somatotropic axis. The published literature routinely examines these compounds together for dual-pathway somatotroph activation studies, as the two receptor systems converge on complementary intracellular signaling mechanisms in pituitary somatotrophs. Global Peptide Shop UK offers the CJC-IPA blend for researchers investigating this paired approach.

Ipamorelin 5mg is Frequently Paired With

• CJC-1295 No DAC — Available as CJC-IPA Blend.
• Tesamorelin 5mg — Available as Ipa/Tesa Blend.
• Sermorelin 5mg — Alternative GHRH analog pairing.

Quality and Testing

Every lot of Peptide Global Peptide Shop ipamorelin is manufactured in the United States and verified by independent third-party analytical laboratories. Testing includes HPLC purity analysis (≥99%), mass spectrometry for molecular identity and sequence confirmation, and endotoxin screening.

Storage

• Lyophilized: Store at -20°C, protected from light and moisture
• Reconstituted: 2-8°C, use within 30 days
• Avoid repeated freeze-thaw cycles

References

1. Raun K, et al. European Journal of Endocrinology. 1998;139(5):552-561. PubMed 9849822
2. Sinha DK, et al. Transl Androl Urol. 2020;9(Suppl 2):S149-S159. PMC7108996
3. Gobburu JVS, et al. Pharmaceutical Research. 1999;16:1412-1416.
4. Holst B, et al. Molecular Endocrinology. 2003;17(11):2201-2210. PubMed 12893882
5. Svensson J, et al. The Journal of Endocrinology. 2000.
6. Greenwood-Van Meerveld B, et al. J Exp Pharmacol. 2012;4:149-155. PubMed 27186124

For laboratory research use only. Not for human or veterinary use.